During the last several years, many new evidence and data sources have become available to the life insurance industry.
 

Suppose insurers could throw away their old playbook and envision the future of insurance, unencumbered by exhausted methods, slow-moving platforms, and legacy constraints. What new possibilities would come to light?
 

This article is the introduction part of the footprint analysis series, focusing on the medical discussion on Alzheimer’s and dementia. It covers basic information about the diseases, progress in risk detention, risk reduction and prevention, and advances in treatment. It also discusses how the progress and emission of Alzheimer’s and dementia may affect the life insurance, critical illness, and long-term care businesses.